Benzinga | Nov 9, 2021 11:36AM EST

ContraFect's New Data Presented At NACFC Demonstrate Potential Of Direct Lytic Agents To Treat Pulmonary Infections In Patients With Cystic Fibrosis

ContraFect Corporation (NASDAQ:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that data from the Company's DLA programs, including lysin CF-370 and amurin peptide AM1, demonstrate the potential for their development as treatments for pulmonary infections associated with cystic fibrosis. These data were recently presented at the North American Cystic Fibrosis Conference (NACFC) which was held virtually from November 2-5, 2021.



These direct lytic agents show in vitro activity against the most prevalent Gram-negative pathogens, including multi-drug resistant (MDR) strains commonly associated with pulmonary infections in patients with cystic fibrosis. Nine of these MDR strains were evaluated. Currently, few treatment options exist to address these infections, and persons with cystic fibrosis are even more vulnerable. The data further support the in vitro activity profile of CF-370 and AM1 against specific Gram-negative pathogens, including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Achromobacter spp.

Raymond Schuch, Ph.D., Vice President, Research, ContraFect Corporation, delivered the poster presentation entitled "Direct Lytic Agents (DLAs), a Novel Family of Antimicrobial Agents, Exert Potent in vitro Bactericidal Activity Against Gram-negative (GN) Pathogens Which Cause Pulmonary Infections in CF Patients, Including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Achromobacter xylosoxidans". The presentation is available on the Company's website.